PE00252015A1 - Antibodies and immunoconjugates against LY6E and methods of use - Google Patents

Antibodies and immunoconjugates against LY6E and methods of use

Info

Publication number
PE00252015A1
PE00252015A1 PE0020472014A PE0020472014A PE00252015A1 PE 00252015 A1 PE00252015 A1 PE 00252015A1 PE 0020472014 A PE0020472014 A PE 0020472014A PE 0020472014 A PE0020472014 A PE 0020472014A PE 00252015 A1 PE00252015 A1 PE 00252015A1
Authority
PE
Peru
Prior art keywords
nro
id
hvr
sec
antibodies
Prior art date
Application number
PE0020472014A
Other languages
Spanish (es)
Inventor
Peter Chang
Chie Sakanaka
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201261649775P priority Critical
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE00252015A1 publication Critical patent/PE00252015A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015Breast
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023Lung
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303Liver or Pancreas
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

SE REFIERE A UN ANTICUERPO AISLADO QUE SE UNE A LY6E, DONDE EL ANTICUERPO SE UNE A UN EPITOPO DENTRO DE LOS AMINOACIDOS 21-131 DE SEC. CONCERNS an isolated antibody that binds to LY6E, where the antibody binds to an epitope within amino acids 21-131 of SEQ. ID. ID. NRO.: 1. DICHO ANTICUERPO COMPRENDE: a) HVR-H1 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEC. NRO .: 1. said antibody comprises: a) HVR-H1 comprising the amino acid sequence SEQ. ID. ID. NRO.: 10; NRO .: 10; b) HVR-H2 QUE COMPRENDE LA SEC. b) HVR-H2 comprising SEQ. ID. ID. NRO.: 11; NRO .: 11; c) HVR-H3 QUE COMPRENDE LA SEC.ID.NRO.:12; c) HVR-H3 comprising SEC.ID.NRO.:12; d) HVR-L1 QUE COMPRENDE LA SEC.ID.NRO.: 7; d) HVR-L1 comprising SEC.ID.NRO .: 7; e) HVR-L2 QUE COMPRENDE LA SEC.ID.NRO.: 8; e) HVR-L2 comprising SEC.ID.NRO .: 8; f) HVR-L3 QUE COMPRENDE LA SEC.ID.NRO.:9. f) HVR-L3 comprising SEC.ID.NRO.:9. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ES UTIL EN EL TRATAMIENTO DE CANCER. ALSO it REFERS TO A pharmaceutical composition which is useful in the treatment of cancer.
PE0020472014A 2012-05-21 2013-05-20 Antibodies and immunoconjugates against LY6E and methods of use PE00252015A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US201261649775P true 2012-05-21 2012-05-21

Publications (1)

Publication Number Publication Date
PE00252015A1 true PE00252015A1 (en) 2015-02-09

Family

ID=49624486

Family Applications (1)

Application Number Title Priority Date Filing Date
PE0020472014A PE00252015A1 (en) 2012-05-21 2013-05-20 Antibodies and immunoconjugates against LY6E and methods of use

Country Status (25)

Country Link
US (2) US9724427B2 (en)
EP (1) EP2852404B1 (en)
JP (2) JP6192022B2 (en)
KR (1) KR101718200B1 (en)
CN (1) CN104540519B (en)
AR (1) AR091098A1 (en)
AU (2) AU2013266604B2 (en)
BR (1) BR112014028366A2 (en)
CA (1) CA2872327A1 (en)
CL (1) CL2014003140A1 (en)
CO (1) CO7151531A2 (en)
CR (1) CR20140529A (en)
EA (1) EA201491947A1 (en)
HK (2) HK1208167A1 (en)
IL (1) IL235542D0 (en)
MA (1) MA37538B1 (en)
MX (1) MX352581B (en)
NZ (1) NZ702195A (en)
PE (1) PE00252015A1 (en)
PH (1) PH12014502601A1 (en)
SG (1) SG11201407561UA (en)
TW (1) TWI614265B (en)
UA (1) UA114814C2 (en)
WO (1) WO2013177055A2 (en)
ZA (1) ZA201408236B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201603125SA (en) 2013-10-21 2016-05-30 Genentech Inc ANTI-Ly6E ANTIBODIES AND METHODS OF USE
MX2016007851A (en) * 2013-12-16 2016-09-07 Genentech Inc Peptidomimetic compounds and antibody-drug conjugates thereof.
WO2015095223A2 (en) * 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
JP2017504606A (en) * 2013-12-16 2017-02-09 ジェネンテック, インコーポレイテッド Peptidomimetic compounds and antibody-drug conjugates thereof
BR112017003236A2 (en) 2014-09-12 2017-11-28 Genentech Inc cysteine engineered antibodies, drug conjugates and antibodies, drug and antibody conjugate preparation method and pharmaceutical composition
KR20170106965A (en) 2014-12-23 2017-09-22 엔비이-테라퓨틱스 아게 Binding protein drug conjugates comprising anthracycline derivatives
US10017577B2 (en) 2015-06-15 2018-07-10 Genentech, Inc. Antibodies and immunoconjugates
CN108391422A (en) 2015-10-02 2018-08-10 豪夫迈·罗氏有限公司 Pyrrolobenzodiazepines * antibody-drug conjugates and application method
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
CN110139674A (en) 2016-10-05 2019-08-16 豪夫迈·罗氏有限公司 The method for preparing antibody drug conjugate
WO2019077150A1 (en) * 2017-10-20 2019-04-25 Genethon Use of syncytin for targeting drug and gene delivery to lung tissue

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5773223A (en) 1993-09-02 1998-06-30 Chiron Corporation Endothelin B1, (ETB1) receptor polypeptide and its encoding nucleic acid methods, and uses thereof
US5856136A (en) * 1996-07-03 1999-01-05 Incyte Pharmaceuticals, Inc. Human stem cell antigens
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6913756B1 (en) * 1998-04-29 2005-07-05 The Uab Research Foundation Monoclonal antibodies specific for anthrax and peptides derived from the antibodies thereof
US7387772B1 (en) * 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
PT1517921E (en) * 2002-06-28 2006-09-29 Domantis Ltd Differently specified ligands with semi-life in the increased serum
DK2357006T3 (en) 2002-07-31 2015-12-21 Seattle Genetics Inc Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
KR20050048615A (en) * 2002-08-19 2005-05-24 제넨테크, 인크. Compositions and methods for the diagnosis and treatment of tumor
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2005035754A1 (en) 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
ES2557389T3 (en) 2003-11-06 2016-01-25 Seattle Genetics, Inc. Monomethylvaline compounds conjugated with antibodies
SI1704166T1 (en) 2004-01-07 2015-06-30 Novartis Vaccines And Diagnostics, Inc. M-csf-specific monoclonal antibody and uses thereof
US7375078B2 (en) 2004-02-23 2008-05-20 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7949518B2 (en) * 2004-04-28 2011-05-24 Panasonic Corporation Hierarchy encoding apparatus and hierarchy encoding method
KR20120064120A (en) 2004-06-01 2012-06-18 제넨테크, 인크. Antibody drug conjugates and methods
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
US20060094676A1 (en) 2004-10-29 2006-05-04 Ronit Lahav Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
US20070134243A1 (en) 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
WO2007100385A2 (en) 2005-10-31 2007-09-07 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods
JP2009530645A (en) * 2006-03-21 2009-08-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents of The University of California N-cadherin and LY6-E: targets for cancer diagnosis and therapy
US20070269442A1 (en) 2006-05-19 2007-11-22 Robert J. Webber Chimeric monoclonal antibody recognizing iNOS
AU2009270988A1 (en) * 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
SG173812A1 (en) 2009-02-27 2011-09-29 Genentech Inc Methods and compositions for protein labelling
KR20130004579A (en) 2010-02-23 2013-01-11 제넨테크, 인크. Compositions and methods for the diagnosis and treatment of tumor
PT2528625E (en) 2010-04-15 2013-10-17 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
JP2013534520A (en) 2010-06-08 2013-09-05 ジェネンテック, インコーポレイテッド Cysteine engineered antibodies and conjugates
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
SG11201603125SA (en) * 2013-10-21 2016-05-30 Genentech Inc ANTI-Ly6E ANTIBODIES AND METHODS OF USE

Also Published As

Publication number Publication date
CR20140529A (en) 2015-02-12
AU2013266604A1 (en) 2015-01-15
BR112014028366A2 (en) 2017-06-27
TWI614265B (en) 2018-02-11
US20160199508A1 (en) 2016-07-14
WO2013177055A2 (en) 2013-11-28
MA37538A2 (en) 2016-11-30
TW201406780A (en) 2014-02-16
MX2014014085A (en) 2015-02-04
JP6192022B2 (en) 2017-09-06
EP2852404A2 (en) 2015-04-01
KR20150013318A (en) 2015-02-04
NZ702195A (en) 2016-09-30
IL235542D0 (en) 2015-01-29
WO2013177055A3 (en) 2014-03-06
ZA201408236B (en) 2016-01-27
EA201491947A1 (en) 2015-05-29
US9724427B2 (en) 2017-08-08
JP2015528692A (en) 2015-10-01
SG11201407561UA (en) 2014-12-30
MX352581B (en) 2017-11-29
JP2017169572A (en) 2017-09-28
PH12014502601A1 (en) 2015-02-02
CL2014003140A1 (en) 2015-02-27
EP2852404B1 (en) 2017-07-26
AU2013266604B2 (en) 2016-09-08
CN104540519B (en) 2018-06-01
UA114814C2 (en) 2017-08-10
MA37538B1 (en) 2017-11-30
HK1208167A1 (en) 2016-02-26
AR091098A1 (en) 2015-01-14
CA2872327A1 (en) 2013-11-28
HK1209373A1 (en) 2016-04-01
EP2852404A4 (en) 2015-12-02
AU2016259286A1 (en) 2016-12-01
US20180015177A1 (en) 2018-01-18
KR101718200B1 (en) 2017-03-21
CN104540519A (en) 2015-04-22
CO7151531A2 (en) 2014-12-29

Similar Documents

Publication Publication Date Title
Weiner Building better monoclonal antibody-based therapeutics
ES2571129T3 (en) Humanized anti-CTLA4 antibodies
AR086579A1 (en) Antigen-binding proteins
ECSP11010823A (en) Neutralizing antibodies to the anti-influenza virus to and uses thereof
AR080794A1 (en) Bivalent bispecific antibodies anti-VEGF / anti-Ang-2
NZ605980A (en) Anti-fap antibodies and methods of use
RU2012135395A (en) Antibodies against folic acid receptor 1, their immuno conjugates and use
CL2013001645A1 (en) Isolated nucleic acid sequence encoding a chimeric antigen receptor, which comprises an antigen-binding domain, a transmembrane domain, a region of costimulatory signaling and CD3 zeta domain signaling; said receiver; cell; vector; and its use to treat a disease associated with elevated expression of a tumor antigen.
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
RS53157B (en) Anti-sclerostin antibodies
AR059922A1 (en) Humanized monoclonal antibodies to hepatocyte growth factor
NZ631405A (en) Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
AR084456A1 (en) Anti-PCSK9 and methods of use
CO6331370A2 (en) Receptor antibodies of advanced glycosylation end products (RAGE) and uses thereof
PE06532016A1 (en) Binding proteins IL-17
RU2011142281A (en) Antibodies to her
PE11802017A1 (en) Anti-PD-1 and methods of use
NZ586047A (en) Anti-vascular endothelial growth factor antibodies
NZ572177A (en) Anti-dll4 antibodies and methods using same
CO6270252A2 (en) Anti-CD79b antibodies and immunoconjugates and methods of use thereof
RU2012142230A (en) Antibodies against human csf-1r and their application
JP2013056896A5 (en)
CR20110161A (en) Human antibodies and uses thereof IL17
PE09792014A1 (en) Fc silent variants of anti-CD40
PE10332016A1 (en) Binding proteins the antigen GITR

Legal Events

Date Code Title Description
FG Grant, registration